1
00:00:00,000 --> 00:00:02,310


2
00:00:02,310 --> 00:00:04,110
BRYAN WOOD: The US Food
and Drug Administration

3
00:00:04,110 --> 00:00:06,360
on Monday granted
the emergency use

4
00:00:06,360 --> 00:00:08,370
of the first
experimental antibody

5
00:00:08,370 --> 00:00:10,590
treatment for COVID-19.

6
00:00:10,590 --> 00:00:14,520
Eli Lilly's bamlanivimab
is a monoclonal antibody,

7
00:00:14,520 --> 00:00:16,890
or a synthetic
copy of an antibody

8
00:00:16,890 --> 00:00:20,130
used by the immune system
to fight infection.

9
00:00:20,130 --> 00:00:23,340
The US government has
purchased 300,000 doses

10
00:00:23,340 --> 00:00:25,620
of the drug, which the
company said it will

11
00:00:25,620 --> 00:00:27,750
begin shipping immediately.

12
00:00:27,750 --> 00:00:30,420
There will be no out-of-pocket
costs for patients,

13
00:00:30,420 --> 00:00:33,270
according to US officials,
although health care

14
00:00:33,270 --> 00:00:36,300
facilities may charge
an administration fee.

15
00:00:36,300 --> 00:00:39,810
Trial data showed that a one
time infusion of Eli Lilly's

16
00:00:39,810 --> 00:00:42,930
treatment reduced the
need for hospitalization

17
00:00:42,930 --> 00:00:47,700
or emergency room visits in
high risk COVID-19 patients.

18
00:00:47,700 --> 00:00:50,550
US regulators have authorized
Eli Lilly's treatment

19
00:00:50,550 --> 00:00:53,070
for patients who have
been recently diagnosed

20
00:00:53,070 --> 00:00:57,540
with mild to moderate
COVID-19, over the age of 65,

21
00:00:57,540 --> 00:01:00,240
and for patients 12
and older who have

22
00:01:00,240 --> 00:01:02,250
an underlying health condition.

23
00:01:02,250 --> 00:01:04,920
The treatment will not be
used on patients already

24
00:01:04,920 --> 00:01:08,520
hospitalized or who
require oxygen therapy,

25
00:01:08,520 --> 00:01:11,100
as a US
government-sponsored study

26
00:01:11,100 --> 00:01:13,500
found it could worsen
the clinical outcome

27
00:01:13,500 --> 00:01:15,390
in these cases.

28
00:01:15,390 --> 00:01:18,270
In an emailed statement, the
White House hailed the FDA's

29
00:01:18,270 --> 00:01:21,030
decision as a major milestone.

30
00:01:21,030 --> 00:01:24,120
US President Donald Trump
received a similar treatment

31
00:01:24,120 --> 00:01:26,430
created by Regeneron
after he was

32
00:01:26,430 --> 00:01:29,550
diagnosed with the
coronavirus in early October.

33
00:01:29,550 --> 00:01:31,770
Regeneron is currently
seeking emergency

34
00:01:31,770 --> 00:01:36,150
approval for a dual antibody
treatment against COVID-19.

35
00:01:36,150 --> 00:01:40,020
Meanwhile, Eli Lilly
anticipates manufacturing up

36
00:01:40,020 --> 00:01:43,020
to 1 million doses
of bamlanivimab

37
00:01:43,020 --> 00:01:46,860
by the end of 2020 for
use around the world

38
00:01:46,860 --> 00:01:49,200
through early next year.

39
00:01:49,200 --> 00:01:50,000